Embryos donated to science blow the whistle on CRISPR
By Alison Motluk,
HeyReprotech Newsletter
| 06. 23. 2020
The controversial gene-editing technique mis-snips again. And thanks to embryos donated to science, we know about it.
Many people, finding themselves at the end of their reproductive journey, decide to donate their extra embryos "to science." We don't hear all that much about what becomes of these embryos — what scientific advancements they enabled, what policies they influenced, what practices they helped to curtail.
Here is one such story.
Twenty-five embryos were volunteered into a study using CRISPR, a controversial gene-editing technique. (For a bit of background on the science and politics of CRISPR, see this round-up.) All the couples who donated their embryos gave informed consent. They were told about the research project, were given an opportunity to receive counselling about their decision, and agreed that any results from their contribution could be published in scientific journals. No money changed hands for the embryos.
Some of the findings generated by studying these embryos ended up in one of the world's most prestigious scientific journals, Nature, in this study about the role of a particular gene (POU5F1) in early embryological development.
But those embryos went on to play a role in a second...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...